Pacific Biosciences of California
PACB
1.63
-0.13
-7.39%
Pacific Biosciences of California
US · PACB
#3373 by market cap
1.63
-0.13
-7.39%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:52
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 13 in the most recent period (2026/Q3).
- Total institutional ownership rose 17.1 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 80.10% +17.09pp
- Institutions
- 247 -13
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund54.91%
Public Company12.39%
Hedge Fund9.41%
Private Company2.38%
Individual/Insider1.01%
VC/PE Fund0.53%
Insurance Company0.31%
Other18.90%
Top holders as of 2026-10-31
T. Rowe Price Group, Inc.
10.69% · 33.45M sh
BlackRock
10.48% · 32.80M sh
ARK Investment Management LLC
9.51% · 29.75M sh
SoftBank Group Corp.
6.54% · 20.45M sh
The Goldman Sachs Group, Inc.
4.52% · 14.14M sh
Vanguard Capital Management, LLC
4.23% · 13.24M sh
Goldman Sachs Asset Management, L.P.
3.00% · 9.38M sh
Amova Asset Management
1.59% · 4.96M sh
Geode Capital Management, LLC
2.12% · 6.63M sh
State Street Global Advisors
1.93% · 6.05M sh
Point72 Asset Management, L.P.
1.54% · 4.79M sh
D. E. Shaw & Co., L.P.
1.35% · 4.21M sh
Two Sigma Investments, LP
1.36% · 4.24M sh
Sumitomo Mitsui Trust Asset Management
1.59% · 4.96M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 35 buys · 14 sells
| Name | Role | Stake |
|---|---|---|
| Christian O. Henry | Senior Business Advisor & Director | 0.40% |
| Mark Van Oene | CEO, President, Director & Interim CFO | 0.32% |
| Kathy Ordonez | Independent Director | 0.13% |
| James Gibson | Chief Financial Officer | 0.05% |
| John Milligan | Independent Chairperson | 0.04% |
| Marshall Mohr | Independent Director | 0.04% |
| Michele Farmer | Former Vice President | 0.03% |
| William Ericson | Independent Director | 0.01% |
| Hannah Valantine | Independent Director | 0.01% |
| Randall Livingston | Independent Director | 0.01% |
| Lucy Shapiro | Former Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-02 | William Meyer | Chief Accounting Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-10-05 | James Gibson | Advisor | Automatic Disposition | -161,815 | $3.11 |
| 2026-10-05 | James Gibson | Advisor | Derivative Exercise and Sale | -500,000 | $1.18–3.11 |
| 2026-08-16 | Mark Van Oene | CEO, President, Director & Interim CFO | Open Market Disposition | -26,911 | $1.13 |
| 2026-08-09 | Mark Van Oene | CEO, President, Director & Interim CFO | Other Acquisition | +489,130 | -- |
| 2026-08-09 | Mark Van Oene | CEO, President, Director & Interim CFO | Other Derivative Acquisition | +1,967,888 | $1.15 |
| 2026-06-02 | William Ericson | Independent Director | Other Derivative Acquisition | +223,492 | $1.58 |
| 2026-06-02 | Kathy Ordonez | Independent Director | Other Derivative Acquisition | +223,492 | $1.58 |
| 2026-06-02 | John Milligan | Independent Chairperson | Other Derivative Acquisition | +223,492 | $1.58 |
| 2026-06-02 | Marshall Mohr | Independent Director | Other Derivative Acquisition | +223,492 | $1.58 |
| 2026-06-02 | Christopher Smith | Former Independent Director | Other Derivative Acquisition | +223,492 | $1.58 |
| 2026-06-02 | Randall Livingston | Independent Director | Other Derivative Acquisition | +223,492 | $1.58 |
| 2026-06-02 | Christopher Gibson | Independent Director | Other Derivative Acquisition | +74,497 | $1.58 |
| 2026-06-02 | Hannah Valantine | Independent Director | Other Derivative Acquisition | +223,492 | $1.58 |
| 2026-04-07 | Christopher Gibson | Independent Director | Other Acquisition | +57,473 | -- |
| 2026-04-07 | Christopher Gibson | Independent Director | Other Derivative Acquisition | +77,842 | $1.52 |
| 2026-03-31 | James Gibson | Advisor | Open Market Disposition | -88,185 | $1.37 |
| 2026-03-02 | Christian O. Henry | Senior Business Advisor & Director | Open Market Disposition | -12,497 | $1.51 |
| 2026-03-02 | Christopher Gibson | Independent Director | Other Acquisition | +53,913 | -- |
| 2026-03-02 | Christopher Gibson | Independent Director | Other Derivative Acquisition | +73,087 | $1.52 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:52:58 · For reference only, not investment advice and not tailored to your situation.
Pacific Biosciences of California discussion 0 comments